What EMBL Ventures does

EMBL Ventures GmbH is a privately held venture capital firm headquartered in Heidelberg, Germany, founded in 2001 to finance and develop life science companies across Europe. The firm invests in companies developing therapeutic treatment modalities, next-generation enabling technology platforms, and diagnostics and medical devices, typically at Series A and later stages. It distinguishes itself through a formalized, longstanding partnership with the European Molecular Biology Laboratory (EMBL) and its technology transfer organization EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), which the firm cites as a structural source of deal flow and diligence access. The firm is led by Managing Directors Dr. Stefan Herr and Dr. Frank Mühlenbeck, with a broader team that includes founding partner Jan Adams and additional managing partners, and operates from two Heidelberg locations (a Boxbergring office and a campus office on Meyerhofstrasse adjacent to EMBL).

The firm generates returns through equity investments in life science companies, with realized exits including ViraTherapeutics' acquisition by Boehringer Ingelheim for EUR 210 million (2018), Luxendo's acquisition by Bruker (2017), and Immatics' NASDAQ listing (2020), alongside portfolio awards such as Scrip's "Licensing Deal of the Year" and the European Mediscience "Emerging Star" (both 2017, for Crescendo Biologics). The active portfolio includes Topas Therapeutics (antigen-specific immune tolerance, with a EUR 40 million Series B total raised by 2021), Allecra Therapeutics (EXBLIFEP, FDA-approved February 2024), Crescendo Biologics (multi-specific immunotherapies, partnered with BioNTech in 2022), and Immatics.

EMBL Ventures employs a sales-led, network-driven go-to-market: deal sourcing is concentrated at the top of the funnel through EMBL/EMBLEM referrals and the partners' scientific network, with hands-on operational support provided directly to portfolio companies. The firm's value proposition rests on capital, scientific expertise, EMBL ecosystem access, and operational assistance through clinical, regulatory, and exit milestones. Distribution is direct (equity investment into portfolio companies), and the firm does not sell a product platform. Revenue mechanics are typical of a small European life science VC: management fees on a single or limited number of fund vehicles, plus carried interest crystallized on exits. No public disclosures of AUM, fund size, LP composition, or annual revenue are available.

Name

EMBL Ventures

Legal name

EMBL Ventures GmbH

Website

https://embl-ventures.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1–10 employees

Short description

EMBL Ventures is a Heidelberg-based venture capital firm investing across Europe in life science companies developing therapeutics, enabling technology platforms, and diagnostics/medical devices, leveraging a structural partnership with EMBL and its technology transfer arm EMBLEM for deal flow and diligence.

Ownership category

akta.pro rank

Product category

Life Science Venture Capital

NAICS

Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Life science venture capital
• Healthcare investment
• Biotech financing
• Therapeutics investment
• Medical device investment

Headquarters

HQ city

Heidelberg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns: EMBL Ventures generates returns through equity investments in life science companies, with exits via M&A, licensing agreements, and IPOs. The firm participates in funding rounds of portfolio companies and realizes gains upon exit events.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

EMBL Ventures is a Heidelberg-based venture capital firm that invests throughout Europe in life science companies developing novel therapeutic treatment modalities, next-generation enabling technology platforms, and innovations in diagnostics and medical devices. The firm provides direct equity investment capital (typically Series A and later), hands-on operational support, and portfolio companies benefit from unique access to the European Molecular Biology Laboratory (EMBL) scientific network through its technology transfer arm EMBLEM.

Product overview

EMBL Ventures is a venture capital firm headquartered in Heidelberg, Germany, that provides investment services to life science companies. Rather than offering a unified product platform, the firm operates as an investor supporting portfolio companies across Europe. Their offering encompasses direct investment capital, hands-on operational support, access to their scientific and industry network, and unique proximity to the European Molecular Biology Laboratory (EMBL) ecosystem including its technology transfer organization EMBLEM. The firm focuses on companies developing therapeutic treatment modalities, next-generation enabling technology platforms, and innovations in diagnostics and medical devices.

Differentiator

Problem solved

Functional benefit

Products and services

• Life science venture capital investment

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• European Molecular Biology Laboratory (EMBL)coreStrategic or Co-development PartnerEMBL Ventures has a close relationship with the European Molecular Biology Laboratory. EMBL is at the forefront of life sciences research, innovation, technology development and transfer. The Laboratory is housed at six sites in Europe (headquarter Heidelberg) and has more than 1,600 staff from 80 nations whose research and expertise cover the whole spectrum of molecular biology.
• EMBL Enterprise Management Technology Transfer GmbH (EMBLEM)coreStrategic or Co-development PartnerEMBLEM identifies, protects and commercialises the intellectual property developed in the EMBL-world, from EMBL-alumni and from third parties. EMBLEM's pro-active technology transfer approach facilitates and accelerates the transfer of innovative technology from basic research to industry.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BioMedPartners: BioMedPartners is a Switzerland-based VC firm focused on early- and growth-stage life sciences investments across Europe. Comparable as a European life sciences VC with similar stage and therapeutic focus.
• Forbion: Forbion is a leading European life sciences venture capital firm investing in therapeutics and enabling technologies. Directly comparable as a European healthcare-focused VC with multiple funds and similar therapeutic/technology focus to EMBL Ventures.
• Kurma Partners: Kurma Partners is a Paris-based VC firm focused on healthcare and life sciences across Europe. Directly comparable as a European life sciences-only VC investing in therapeutics, diagnostics, and digital health.
• Medicxi: Medicxi is a European life sciences-focused investment firm with offices in Switzerland, the UK, and Italy. Directly comparable as a European life sciences-only VC with therapeutics and platform focus.
• Life Sciences Partners (LSP): LSP is a Netherlands-based life sciences and healthcare VC firm investing across Europe. Directly comparable as a European life sciences VC with similar therapeutic focus and growth-stage investment approach.

Others

• EMBL Enterprise Management Technology Transfer GmbH (EMBLEM): EMBLEM is EMBL's technology transfer organization and a close strategic partner of EMBL Ventures. While not a competing VC, EMBLEM is the primary deal-sourcing infrastructure for EMBL Ventures and a key ecosystem participant in commercializing EMBL research.

Broad incumbents

• EQT Life Sciences (formerly LSP-Life Sciences Partners): EQT Life Sciences is the life sciences arm of EQT, a large global private equity firm. Comparable as a healthcare/life sciences growth investor but operates with significantly larger AUM and broader geographic reach than EMBL Ventures.
• Boehringer Ingelheim Venture Fund: Boehringer Ingelheim Venture Fund is the corporate VC arm of Boehringer Ingelheim, investing in early-stage life sciences. Comparable as a European life sciences investor with therapeutics focus, though embedded within a large pharmaceutical parent.
• M Ventures: M Ventures is the corporate VC arm of Merck KGaA investing across life sciences, technology, and healthcare. Comparable in European life sciences investing but with broader mandate and corporate backing.

Regional players

• High-Tech Gründerfonds (HTGF): HTGF is a German public-private venture capital investor focused on technology and life sciences startups. Comparable as a Germany-based early-stage investor, though broader across tech and life sciences than EMBL Ventures' focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EMBL Ventures